NAGE Relative Valuation
NAGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAGE is overvalued; if below, it's undervalued.
Historical Valuation
Niagen Bioscience Inc (NAGE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 28.55 is considered Undervalued compared with the five-year average of 61.52. The fair price of Niagen Bioscience Inc (NAGE) is between 7.79 to 17.31 according to relative valuation methord. Compared to the current price of 6.67 USD , Niagen Bioscience Inc is Undervalued By 14.35%.
Relative Value
Fair Zone
7.79-17.31
Current Price：6.67
14.35%
Undervalued
29.30
PE
1Y
3Y
5Y
Trailing
Forward
18.84
EV/EBITDA
Niagen Bioscience Inc. (NAGE) has a current EV/EBITDA of 18.84. The 5-year average EV/EBITDA is 39.13. The thresholds are as follows: Strongly Undervalued below 11.06, Undervalued between 11.06 and 25.10, Fairly Valued between 53.17 and 25.10, Overvalued between 53.17 and 67.21, and Strongly Overvalued above 67.21. The current Forward EV/EBITDA of 18.84 falls within the Undervalued range.
27.94
EV/EBIT
Niagen Bioscience Inc. (NAGE) has a current EV/EBIT of 27.94. The 5-year average EV/EBIT is 56.98. The thresholds are as follows: Strongly Undervalued below 17.96, Undervalued between 17.96 and 37.47, Fairly Valued between 76.48 and 37.47, Overvalued between 76.48 and 95.99, and Strongly Overvalued above 95.99. The current Forward EV/EBIT of 27.94 falls within the Undervalued range.
3.60
PS
Niagen Bioscience Inc. (NAGE) has a current PS of 3.60. The 5-year average PS is 5.27. The thresholds are as follows: Strongly Undervalued below 2.83, Undervalued between 2.83 and 4.05, Fairly Valued between 6.49 and 4.05, Overvalued between 6.49 and 7.71, and Strongly Overvalued above 7.71. The current Forward PS of 3.60 falls within the Undervalued range.
17.32
P/OCF
Niagen Bioscience Inc. (NAGE) has a current P/OCF of 17.32. The 5-year average P/OCF is 36.97. The thresholds are as follows: Strongly Undervalued below 9.32, Undervalued between 9.32 and 23.14, Fairly Valued between 50.80 and 23.14, Overvalued between 50.80 and 64.62, and Strongly Overvalued above 64.62. The current Forward P/OCF of 17.32 falls within the Undervalued range.
20.96
P/FCF
Niagen Bioscience Inc. (NAGE) has a current P/FCF of 20.96. The 5-year average P/FCF is 53.74. The thresholds are as follows: Strongly Undervalued below -13.19, Undervalued between -13.19 and 20.28, Fairly Valued between 87.21 and 20.28, Overvalued between 87.21 and 120.67, and Strongly Overvalued above 120.67. The current Forward P/FCF of 20.96 falls within the Historic Trend Line -Fairly Valued range.
Niagen Bioscience Inc (NAGE) has a current Price-to-Book (P/B) ratio of 7.38. Compared to its 3-year average P/B ratio of 11.87 , the current P/B ratio is approximately -37.80% higher. Relative to its 5-year average P/B ratio of 11.87, the current P/B ratio is about -37.80% higher. Niagen Bioscience Inc (NAGE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.77%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.77% , the current FCF yield is about -100.00% lower.
7.58
P/B
Median3y
11.87
Median5y
11.87
4.04
FCF Yield
Median3y
2.77
Median5y
2.77
Competitors Valuation Multiple
The average P/S ratio for NAGE's competitors is , providing a benchmark for relative valuation. Niagen Bioscience Inc Corp (NAGE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 32.86%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NAGE increased by 26.18% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 7.34 to 13.47.
The secondary factor is the Revenue Growth, contributed 32.86%to the performance.
Overall, the performance of NAGE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Niagen Bioscience Inc (NAGE) currently overvalued or undervalued?
What is Niagen Bioscience Inc (NAGE) fair value?
How does NAGE's valuation metrics compare to the industry average?
What is the current P/B ratio for Niagen Bioscience Inc (NAGE) as of Dec 05 2025?
What is the current FCF Yield for Niagen Bioscience Inc (NAGE) as of Dec 05 2025?
What is the current Forward P/E ratio for Niagen Bioscience Inc (NAGE) as of Dec 05 2025?